SCHEMBL13620618

SCHEMBL13620618

CC(=O)Oc1ccc2c3c(ccc2c1)C1(OC(=O)c2cc(C(C)=O)ccc21)c1ccc2cc(OC(C)=O)ccc2c1O3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
GSTP1 P09211 1/20 0.51
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
FTO Q9C0B1 1/20 0.38
GAPDH P04406 3/20 0.38
GNG2 P59768 1/20 0.37
GNB1 P62873 1/20 0.37
HPGD P15428 2/20 0.36
KDM4E B2RXH2 5/20 0.36
GLA P06280 3/20 0.36
POLB P06746 2/20 0.36
GAA P10253 2/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31110328 0.89 MAPT (0.69) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL13146300 0.84 GSTP1 (0.47) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL10378226 0.83 MEN1 (0.52) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL5267867 0.83 MAPT (0.77) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL18677730 0.83 MAPT (0.77) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL15274921 0.81 GSTP1 (0.44) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL5267339 0.79 GSTP1 (0.47) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL14653307 0.78 MAPT (0.66) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL6663204 0.75 MEN1 (0.75) MAPTALDH1A1MEN1KMT2AUSP2
SCHEMBL29485015 0.75 MEN1 (0.75) MAPTALDH1A1MEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204430-B1 CONJUGATES AND METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE FOR TRANSPORTING MOLECULES VIA BIOLOGICAL MEMBRANES SANOFI AVENTIS DEUTSCHLAND (DE) 2009-11-04 EP disclosed
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES EPCAM, ABCB1, ABCB11 MAPT 2324/4885ALDH1A1 1284/4885MEN1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.